DOCSLIB.ORG

Exploring Relief and Managing Side Effects of This Activity Issupported Byan Educationalgrant from Astrazeneca

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exploring Relief and Managing Side Effects of This Activity Issupported Byan Educationalgrant from Astrazeneca JOURNAL SUPPLEMENT A CME/CE Supplement to PWJ—PAINWeek Journal Exploring Relief and of Effects Side Managing RELEASE DATE: December 1, 2014 EXPIRATION DATE: December 31, 2015 Sponsored by Global Education Group. Med Learning Group is the education partner. This activity is supported by an educational grant from AstraZeneca. Faculty Program Overview Sanford M. Silverman, MD This case-based enduring activity will cover the personalized care of patients with Medical Director chronic pain. Comprehensive Pain Medicine Target Audience Pompano Beach, Florida This activity is designed to meet the educational needs of frontline clinicians who care for patients with chronic pain such as physicians, nurse practitioners, physician assistants, and pharmacists. Learning Objectives Upon completion of the program, attendees should be able to: - Discuss the different classes of analgesics used in the treatment of chronic pain, and their safety, efficacy and indications - Recognize the most common opioid-induced side effects, OIC, and the impact of treatments on analgesia - Identify attitudes, barriers and facilitators to communicating with patients about their bowel habits - Identify treatments used for the management of OIC Physician Accreditation Statement- Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physician Credit Designation- Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Continuing Education- Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA. This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Accreditation Statement- Global Education Group (Global) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Credit Designation- Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-14-170-H01-P). This is a knowledge based activity. Nurse Practitioner Continuing Education- Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 11021. This program has been approved for 0.25 contact hours of continuing education (1.0 Pharmacology hours). Physician Assistants - AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program. 1 Exploring Relief and Managing Side Effects of Instructions to Receive Credit- There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CE credit participants must: - Read the learning objectives and faculty disclosures. - Complete the pre-test through this link: https://www.research.net/s/PainSupppre - Participate in the activity. - Complete the post-test and activity evaluation through this link: https://www.research.net/s/Painsupppost - Physicians who successfully complete the post-test and evaluation will receive CME credit. - All non-physician participants who successfully complete the post-test and evaluation will receive a certificate of participation. All certificates will be emailed within 30 days. Fee & Refund/Cancellation Policy- There is no fee for this educational activity. Disclosure of Conflicts of Interest- Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Faculty or Presenter Reported Financial Relationship Sanford M. Silverman, MD Nothing to disclose The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Planner or Manager Reported Financial Relationship Ashley Marostica, RN, MSN Nothing to disclose Amanda Glazar, PhD Nothing to disclose Matthew Frese Nothing to disclose Andrea Funk Nothing to disclose Christina Gallo Nothing to disclose Melissa Johnson Nothing to disclose Cheryl Zigrand Nothing to disclose Disclosure of Unlabeled Use- This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer- Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 2 The PAINWeekEnd™ Educational Summit Series brings live education Hypogonadism and likely hypogonadotropic hypogonadism have about pain management to healthcare professionals through regional correlated with side effects in men such as sexual dysfunction, professional conferences. Each conference also includes an accredited depression, and decreased energy levels. Chronic opioid continuing medical education activity hosted by a faculty chairperson. administration can lead to decreases in testosterone in a dose- This supplement is designed to capture and expand upon some of the dependent manner. Women can also have hormonal side effects of content of the PAINWeekEnd™ live program in print form. The opioids, such as depression, dysmenorrhea, sexual dysfunction, and management of chronic pain with opioids and the ensuing side reduced bone mineral density.4 effects will be discussed, with a particular focus on opioid-induced Hyperalgesia or hyperalgia is an increased sensitivity to pain that constipation (OIC), and how to communicate with patients about presents as increased pain despite increasing doses of opioids. constipation. Long-term opioid use or use of high doses may be associated with the development of hyperalgesia, which may be related to opioid CHRONIC PAIN OVERVIEW metabolites and opioid-induced cell apoptosis.4 The Institute of Medicine has estimated that more than 100 million Americans are living with pain that lasts from weeks to years, and that OPIOID-INDUCED CONSTIPATION 1 the financial costs of chronic pain total up to $635 billion annually. Constipation is an extremely common side effect of opioid treatment, The high prevalence of chronic pain goes hand in hand with high rates occurring in 40% to 95% of patients, with the possibility of occurring of opioid therapy. Sales of opioid analgesics quadrupled between 1999 after just a single dose.5 And, with the increase in the use of opioids, and 2010, with more than 256 million opioid prescriptions filled in 2009 the absolute numbers of patients affected by OIC is also growing.8 2 alone. Opioid therapy is not without its side effects, though, and In patients who require chronic analgesia, constipation can be a clinicians must be aware of the common side effects and ready to debilitating side effect that negatively impacts quality of life.4,9 With up address them in a timely manner to prevent its toxicity from to 56% of patients discontinuing their opioid treatment due to lack of outweighing its effectiveness in treating pain. Of the side effects efficacy or side effects, addressing constipation is critical.3,10 commonly associated with opioid use, constipation is the most prevalent.3 Opioid-induced constipation (OIC) is an expected part of While OIC can occur in any patient treated with opioids, there are opioid treatment that is unlikely to improve over time, and so it should certain risk factors that can increase a patient’s likelihood of be closely monitored and treated prophylactically, with a bowel regimen developing
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
    Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents INTRODUCTION Irritable bowel syndrome (IBS) is a gastrointestinal disorder that most commonly manifests as chronic abdominal pain and altered bowel habits in the absence of any organic disorder (Wald 2017). IBS may consist of diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), IBS with a mixed symptomatology (IBS-M), or unclassified IBS (IBS-U). Switching between the subtypes of IBS is also possible (Ford et al 2014). IBS is a functional disorder of the gastrointestinal tract characterized by abdominal pain, discomfort, and bloating, as well as disturbed bowel habit. The exact pathogenesis of the disorder is unknown; however, it is believed that altered gastrointestinal tract motility, visceral hypersensitivity, autonomic dysfunction, and psychological factors indicate disturbances within the enteric nervous system, which controls the gastrointestinal system (Andresen et al 2008, Ford et al 2009). Prevalence estimates of IBS range from 5 to 15%, and it typically occurs in young adulthood (Ford et al 2014). IBS-D is more common in men, and IBS-C is more common in women (World Gastroenterology Organization [WGO], 2015). Symptoms of IBS often interfere with daily life and social functioning (WGO 2015). The general goals of therapy are to alleviate the patient’s symptoms and to target any specific exacerbating factors (eg, medications, dietary changes), concerns about serious illness, stressors, or potential psychiatric comorbidities that may exist (Wald 2015). Non-pharmacological interventions to combat IBS symptoms include dietary modifications such as exclusion of gas- producing foods (eg, beans, prunes, Brussel sprouts, bagels, etc.), trials of gluten avoidance, and consumption of probiotics, as well as psychosocial therapies (eg, hypnosis, biofeedback, etc.) (Ford et al 2014).
    [Show full text]
  • 208854Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208854Orig1s000 SUMMARY REVIEW OND=Office of New Drugs OPQ=Office of Pharmaceutical Quality OPDP=Office of Prescription Drug Promotion OSI=Office of Scientific Investigations CDTL=Cross-Discipline Team Leader COA=Clinical Outcome Assessment CSS=Controlled Substance Staff DAAAP= Division of Anesthesia, Analgesia, and Addiction Products OSE= Office of Surveillance and Epidemiology DEPI= Division of Epidemiology DMEPA=Division of Medication Error Prevention and Analysis DPMH = Division of Pediatric and Maternal Health MHT=Maternal Health Team Quality Review Team DISCIPLINE REVIEWER BRANCH/DIVISION Drug Substance Joseph Leginus CDER/OPQ/ONDP/ DNDAPI/NDBII Drug Product Sarah Ibrahim CDER/OPQ/ONDP/ DNDPII/NDPBV Process Zhao Wang CDER/OPQ/OPF/ DPAI/PABI Microbiology Zhao Wang CDER/OPQ/OPF/ DPAI/PABI Facility Donald Lech CDER/OPQ/OPF/DIA/IABIII Biopharmaceutics Peng Duan CDER/OPQ/ONDP/ DB/BBII Regulatory Business Cheronda Cherry-France CDER/OND/ODEIII/ DGIEP Process Manager Application Technical Lead Hitesh Shroff CDER/OPQ/ONDP/ DNDPII/NDPBV Laboratory (OTR) N/A N/A ORA Lead Paul Perdue Jr. ORA/OO/OMPTO/ DMPTPO/MDTP Environmental Analysis James Laurenson CDER/OPQ/ONDP (EA) 2 Reference ID: 4073992 1. Benefit-Risk Assessment I concur with the reviewers’ conclusions that the benefit/risk of naldemedine is favorable in the population for which this product will be approved and that the risks can be managed with labeling. The applicant proposed the following indication for naldemedine, an orally administered peripheral mu opioid receptor antagonist: Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
    [Show full text]
  • Functional Bowel Disorders
    FUNCTIONAL BOWEL DISORDERS Fermín Mearin, M.D. Institute of Functional and Motor Digestive Disorders, Centro Médico Teknon, Barcelona, Spain. Brian E. Lacy, Ph.D., M.D. Dartmouth-Hitchcock Medical Center, Lebanon, NH. USA. Lin Chang, M.D. David Geffen School of Medicine at UCLA. Los Angeles, CA. USA. William D. Chey, M.D. University of Michigan Health System, Ann Arbor, MI. USA. Anthony J. Lembo, M.D., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA. USA. Magnus Simren, Ph.D., M.D. University of Gothenburg, Gothenburg, Sweden. Robin Spiller, M.B., BChir., MSc., M.D. Cantab, University of Nottingham, UK. 1 INTRODUCTION Functional Bowel Disorders Classification Functional bowel disorders (FBDs) are a spectrum of chronic gastrointestinal disorders, attributable to the middle or lower gastrointestinal tract, characterized by the following predominant symptoms or signs: abdominal pain, abdominal bloating, abdominal distension and bowel habit abnormalities (which include constipation, diarrhea, or mixed constipation and diarrhea). Functional bowel disorders (FBDs) can be classified into 5 distinct categories: irritable bowel syndrome (IBS); functional constipation (FC); functional diarrhea (FDr); functional abdominal bloating/distention (FAB/D); and unspecified FBD (U-FBD). Although categorized as distinct disorders, significant overlap exists, and in some cases it may not be possible to confidently distinguish them. The FBDs can be conceptualized in 3 ways (see Figure 1): 1. As distinct conditions that occur independently; 2. As distinct pathophysiologic conditions with symptoms that frequently overlap; and 3. As a spectrum of pathophysiologic disorders that frequently overlap and which are characterized by patient specific differences in the quantity, intensity and severity of symptom expression.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Mai Muuttunut Piu Miu Miui
    MAIMUUTTUNUT US009943513B1 PIU MIU MIUI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 ,513 B1 Hughey et al. (45 ) Date of Patent: * Apr . 17 , 2018 (54 ) OPIOID ABUSE DETERRENT DOSAGE (58 ) Field of Classification Search FORMS None See application file for complete search history . (71 ) Applicant : BANNER LIFE SCIENCES LLC , High Point , NC (US ) (56 ) References Cited ( 72 ) Inventors : Justin Hughey , Asheboro , NC (US ) ; U . S . PATENT DOCUMENTS Saujanya Gosangari, Jamestown, NC (US ) ; Chue Hue Yang , Greensboro , NC 4 , 828 ,836 A 5 / 1989 Miller 4 ,861 , 598 A 8 / 1989 Oshlack (US ) 4 , 970 ,075 A 11/ 1990 Oshlack 5 ,266 ,331 A 11/ 1993 Oshlack (73 ) Assignee : BANNER LIFE SCIENCES LLC , 5 , 273 , 760 A 12 / 1993 Oshlack High Point, NC (US ) 5 , 286 ,493 A 2 / 1994 Oshlack 5 ,472 , 943 A 12 / 1995 Crain 5 , 478 , 577 A 12 / 1995 Kaiko ( * ) Notice : Subject to any disclaimer, the term of this 5 , 529 , 787 A 6 / 1996 Ayer patent is extended or adjusted under 35 5 , 549 , 912 A 8 / 1996 Kaiko U . S . C . 154 ( b ) by 0 days. 5 ,656 , 295 A 8 / 1997 Oshlack 5 ,672 , 360 A 9 / 1997 Kaiko This patent is subject to a terminal dis 5 , 702 , 725 A 12 / 1997 Chadha claimer . 5 ,914 ,131 A 6 / 1999 Ayer 5 ,958 , 452 A 9 / 1999 Oshlack ( 21) Appl . No. : 15 /285 ,837 5 , 965 , 161 A 10 / 1999 Oshlack 6 , 228 , 863 B1 5 /2001 Kaiko ( 22 ) Filed : Oct . 5 , 2016 6 , 261, 599 B1 7 / 2001 Huang Related U .
    [Show full text]
  • Biodelivery Sciences Announces Significant Additional Insurance Coverage for Both BELBUCA® and Symproic®
    BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic® October 1, 2019 Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C., Oct. 01, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that a major PBM will begin providing improved patient access to BELBUCA® (buprenorphine buccal film), CIII, and Symproic® (naldemedine) tablets 0.2 mg beginning October 1, 2019, with full plan adoption by January 1, 2020. This will enable approximately 14 million covered lives within both commercial and health exchange plans to access BELBUCA as either the preferred or preferred exclusive buprenorphine product within their respective plans and Symproic as the preferred exclusive product within its class. The addition of this large national PBM brings the total number of commercial lives with preferred access to BELBUCA to more than 104 million (out of more than 160 million with coverage) and more than 76 million overall covered lives for Symproic. “We continue to see growing recognition by payers for the clinical value of BELBUCA and the importance to ensure appropriate access and reimbursement for buprenorphine products as emphasized by the HHS led Pain Management Best Practices inter-Agency Task Force report,” stated Scott Plesha, President and Chief Commercial Officer of BDSI. We remain committed to further building upon this momentum and ensuring all patients in the US have appropriate access to BELBUCA.
    [Show full text]
  • Opioid Therapy Duration Before Naldemedine Treatment Is A
    Okamoto et al. Journal of Pharmaceutical Health Care and Sciences (2021) 7:3 https://doi.org/10.1186/s40780-020-00187-3 RESEARCH ARTICLE Open Access Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study Akiharu Okamoto1,2, Kenji Ikemura3, Eri Mizutani1, Takuya Iwamoto1,2* and Masahiro Okuda3 Abstract Background: The most common adverse event (AE) associated with opioid analgesics is opioid-induced constipation (OIC). Naldemedine (NAL) is widely used for the treatment of OIC. However, diarrhea has been reported as the most common treatment-emergent AE of NAL, and little is known about the risk factors associated with the development of diarrhea during NAL administration. This study examined the risk factors for NAL-induced diarrhea via a retrospective chart review of hospitalized patients. Methods: The data of 101 hospitalized adult patients who received NAL for the first time for the treatment of OIC at Mie University Hospital between June 2017 and December 2018 were extracted from electronic medical records. According to the inclusion and exclusion criteria, 70 of the 101 patients were enrolled in this study. Diarrhea was defined as “diarrhea” on the medical record within 2 weeks of NAL administration. Univariate and multivariate analyses were performed to identify risk factors for the development of diarrhea in patients receiving NAL. Results: Twenty-two of the 70 patients enrolled (31%) developed diarrhea within 2 weeks of NAL administration. The median duration (range) of NAL treatment before diarrhea onset was 3 (1–12) days. Patients with diarrhea had a significantly longer duration of opioid therapy before NAL administration than patients without diarrhea (P=0.002).
    [Show full text]
  • Comparing the Effectiveness of Magnesium Oxide and Naldemedine in Preventing Opioid-Induced Constipation
    Ozaki et al. Trials (2020) 21:453 https://doi.org/10.1186/s13063-020-04385-0 STUDY PROTOCOL Open Access Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study Anna Ozaki1†, Takaomi Kessoku1,2†, Michihiro Iwaki1, Takashi Kobayashi1, Tsutomu Yoshihara1,2, Takayuki Kato3, Yasushi Honda1,2, Yuji Ogawa1, Kento Imajo1, Takuma Higurashi1, Masato Yoneda1, Masataka Taguri4, Takeharu Yamanaka4, Hiroto Ishiki5, Noritoshi Kobayashi6, Satoru Saito1, Yasushi Ichikawa2,6 and Atsushi Nakajima1* Abstract Background: Patients taking opioids are known to develop opioid-induced constipation (OIC), which reduces their quality of life. The aim of this study is to compare magnesium oxide with naldemedine and determine which is more effective in preventing OIC. Methods: This proof-of-concept, prospective, randomized controlled trial commenced in Japan in March 2018. Initially, a questionnaire-based survey will be conducted targeting adult patients with cancer who concomitantly commenced opioid treatment and OIC prevention treatment. Patients will then be randomly allocated to a magnesium oxide group (500 mg thrice daily) or a naldemedine group (0.2 mg once daily). Each drug will be orally administered for 12 weeks. The primary endpoint is defined as any improvement in scores on the Japanese version of Patient Assessment of Constipation Quality of Life questionnaire (JPAC-QOL) from baseline to 2 weeks of treatment. Discussion: The primary endpoint is change in JPAC-QOL score from baseline to 2 weeks of intervention. The key secondary endpoint will be change in spontaneous bowel movements at 2 and 12 weeks of intervention.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]